Form 4: Alumis CEO Martin Babler Reports Significant Stock Option Grant and Share Acquisition

Alumis Inc.'s President, CEO, and Chairman, Martin Babler, reported the acquisition of 3,000 common shares and a grant of 812,000 stock options with a strike price of $3.95.

Summary

• Martin Babler, President, CEO, and Chairman of Alumis Inc., reported new beneficial ownership and derivative security transactions.
• Acquired 3,000 shares of common stock on May 20, 2025, under the Issuer's 2024 Employee Stock Purchase Plan.
• Received a grant of 812,000 stock options (comprising 662,000 and 150,000 options) on July 29, 2025.
• The granted stock options have an exercise price of $3.95 per share and are set to expire on July 28, 2035.
• The vesting schedule for the options dictates that 25% will vest on July 29, 2026, with the remaining shares vesting in equal monthly installments over the subsequent 36 months, contingent on continuous service.
• Beneficially owns 106,454 shares indirectly through the Martin Babler revocable trust UAD October 25, 2006, for which he serves as a trustee.

Sentiment

Score: 7

Explanation: The filing indicates a significant equity grant to the CEO, aligning his interests with long-term company performance. This is generally a positive signal for corporate governance and management commitment, although it's a standard compensation event rather than a direct operational or financial achievement.

Positives

• The grant of 812,000 stock options to the CEO aligns management incentives with long-term shareholder value creation.
• The acquisition of 3,000 shares through the Employee Stock Purchase Plan demonstrates direct investment by the CEO in the company, signaling confidence.

Future Outlook

The vesting schedule for the newly granted stock options extends over the next three years, indicating a long-term incentive structure for the CEO tied to the company's future performance.

Industry Context

This filing is a standard insider transaction disclosure, reflecting a compensation event for a key executive. It does not provide broader industry context or trends, but it is common for executives in the biotechnology or pharmaceutical sector (implied by 'ALMS' and 'Alumis Inc.') to receive significant equity-based compensation.

Comparison to Industry Standards

• This Form 4 filing details an executive compensation event, specifically a stock option grant and share acquisition. Direct comparisons to specific companies or projects are not applicable as this filing does not contain performance metrics or project updates.
• Large stock option grants are a common component of executive compensation packages in the biotechnology and pharmaceutical industries, designed to align executive incentives with long-term shareholder value creation.
• The vesting schedule for the options, with an initial cliff and subsequent monthly vesting over several years, is typical for such executive equity grants in the industry.

Corporate Governance

Related Party Transactions

• Martin Babler indirectly beneficially owns 106,454 shares through the Martin Babler revocable trust UAD October 25, 2006, for which he serves as a trustee.

Stakeholder Impact

• Shareholders: The significant stock option grant to the CEO aligns management's long-term interests with shareholder value creation, potentially fostering confidence in leadership.
• Employees: The mention of the '2024 Employee Stock Purchase Plan' suggests broader employee equity participation, which can boost morale and retention.

Next Steps

• The vesting of 25% of the granted stock options on July 29, 2026.
• Subsequent monthly vesting of the remaining stock options over 36 months, contingent on continuous service.
• Potential exercise of stock options by Martin Babler upon vesting and favorable market conditions.

Key Dates

Recommendation

This Form 4 filing primarily details a routine executive compensation event (stock option grant and ESPP share acquisition) for the CEO. While the large option grant aligns management incentives with long-term performance, it does not provide new operational or financial data that would significantly alter the fundamental investment thesis for Alumis Inc. It confirms the CEO's continued commitment and equity participation but does not present a catalyst for a 'buy' or 'sell' recommendation based solely on this disclosure. Investors should 'hold' and await further operational updates or financial results.

Keywords

Alumis Inc., ALMS, Martin Babler, SEC Form 4, Insider Trading, Stock Options, Employee Stock Purchase Plan, CEO, Director, Share Acquisition, Equity Incentive Plan, Vesting Schedule